Compare YieldMax AI & Tech Portfolio Option Income ETF (GPTY) vs Nuvation Bio Inc. Class A Common Stock (NUVB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
YieldMax AI & Tech Portfolio Option Income ETF vs Nuvation Bio Inc. Class A Common Stock — how do they compare? YieldMax AI & Tech Portfolio Option Income ETF trades at $43 (market cap $136.17M), while Nuvation Bio Inc. Class A Common Stock trades at $4.95 (market cap $1.71B). The key difference: Nuvation Bio Inc. Class A Common Stock is far larger — about 12.6× YieldMax AI & Tech Portfolio Option Income ETF's market cap, and YieldMax AI & Tech Portfolio Option Income ETF is trading nearer its 52-week high, Nuvation Bio Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold YieldMax AI & Tech Portfolio Option Income ETF for 60 Days and Nuvation Bio Inc. Class A Common Stock for 0 Days on average.
| GPTY | NUVB | |
|---|---|---|
Market Cap | $136.17M | $1.71B |
Volume | 88,095 | 5,448,712 |
Sector | Income / Options Overlay | Health |
52-Week High | $50.52 | $9.54 |
52-Week Low | $34.73 | $3.41 |
Typical Hold Time | 60 Days | 0 Days |
Enterprise Value | — | $1.30B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About YieldMax AI & Tech Portfolio Option Income ETF
GPTY is an actively managed ETF that seeks to provide current income and capital appreciation by holding a concentrated portfolio of 15 to 30 leading AI and technology companies. It utilizes a variety of options strategies, including selling call options on its underlying holdings, to generate weekly distributions while maintaining direct equity exposure to the growth of the AI sector.
Read more on GPTY →About Nuvation Bio Inc. Class A Common Stock
Nuvation Bio Inc. is a biopharmaceutical company focused on oncology, developing novel cancer treatments including taletrectinib (marketed as IBTROZI), a ROS1 inhibitor, and safusidenib, a brain-penetrant IDH1 inhibitor.
Read more on NUVB →
